Why Plus Therapeutics Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Portfolio Pulse from Lisa Levin
Several stocks are experiencing significant pre-market trading movements. Cellectis S.A. (CLLS) surged 152% following strategic collaboration and investment agreements with AstraZeneca. Plus Therapeutics, Inc. (PSTV) rose 11.3% after announcing third-quarter financial results and a share repurchase program. On the downside, WeWork Inc. (WE) dipped 37.3% amid reports of a planned Chapter 11 bankruptcy filing. Paycom Software, Inc. (PAYC) fell 37.1% after reporting worse-than-expected third-quarter sales results and issuing below-estimate FY23 revenue guidance.
November 01, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Paycom Software shares fell 37.1% after the company reported worse-than-expected third-quarter sales results and issued below-estimate FY23 revenue guidance.
The worse-than-expected third-quarter sales results and the below-estimate FY23 revenue guidance are significant negative developments for Paycom Software, which are likely driving the sharp decline in the company's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
WeWork shares dipped 37.3% amid reports of a planned Chapter 11 bankruptcy filing.
The news of a planned Chapter 11 bankruptcy filing is a significant negative development for WeWork, which is likely driving the sharp decline in the company's stock price.
CONFIDENCE 95
IMPORTANCE 100
RELEVANCE 100
POSITIVE IMPACT
Cellectis shares surged 152% following strategic collaboration and investment agreements with AstraZeneca.
The strategic collaboration and investment agreements with AstraZeneca are significant positive developments for Cellectis, which is likely driving the surge in the company's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Plus Therapeutics shares rose 11.3% after the company reported third-quarter financial results and announced a share repurchase program.
The positive third-quarter financial results and the announcement of a share repurchase program are likely driving the increase in Plus Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100